Who makes Low-dose colesevelam?

Low-dose colesevelam is developed by Daiichi Sankyo.

What development phase is Low-dose colesevelam in?

Low-dose colesevelam is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Low-dose colesevelam

Daiichi Sankyo · FDA-approved active Small molecule Quality 3/100

At a glance

Generic name	Low-dose colesevelam
Also known as	Welchol oral suspension
Sponsor	Daiichi Sankyo
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Colesevelam for Children With Type 2 Diabetes (PHASE4)
A Multicenter, Active and Placebo-controlled Study of Enteric Coated Sevelamer in Patients With Mild to Moderate Hypercholesteremia (PHASE2)
Efficacy and Safety of Colesevelam in Pediatric Patients With Genetic High Cholesterol (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Low-dose colesevelam CI brief — competitive landscape report
Low-dose colesevelam updates RSS · CI watch RSS
Daiichi Sankyo portfolio CI